Key Takeaways
- FDA has proposed a regulation finding that N-acetyl-L-cysteine (NAC) is not excluded from the dietary supplement definition in section 201(ff)(3)(B) of the FD&C Act, and that adding NAC to a dietary supplement is not a prohibited act under section 301(ll).
- This is the first time FDA has used its section 201(ff)(3)(B) rulemaking authority, and the rule would create a new 21 CFR 190.1 that FDA could use to list other ingredients in the future.
- Comments are due 60 days after Federal Register publication (scheduled for November 17, 2026), which puts the deadline on January 19, 2027, in Docket No. FDA-2025-N-2699.
- FDA proposes that any final rule take effect immediately on publication. FDA would then withdraw its August 2022 NAC enforcement discretion guidance.
- Once NAC products are lawful dietary supplements, they would be fully subject to dietary supplement requirements, including current good manufacturing practice (CGMP), labeling, and claims rules. FDA could take enforcement action against adulterated or misbranded products.
Background: Why NAC Has Been Excluded
Under section 201(ff)(3)(B)(i) of the FD&C Act, an article approved as a new drug before it was marketed as a dietary supplement or food cannot be a dietary supplement. The only exception is a regulation, issued after notice and comment, finding that the article would be lawful. FDA approved NAC as a new drug (Mucomyst, NDA 013601) on September 14, 1963. The agency says it knows of no supplement or food marketing before that date, and it asks for any contrary evidence. NAC is a dietary ingredient under section 201(ff)(1)(E). It is not a new dietary ingredient, because a 1991 advertisement shows it was marketed before October 15, 1994.
FDA has said NAC is excluded several times: in a July 2001 health claim response (a redacted copy is now being placed in the docket), in a 2010 response to an NDI notification, and in July 2020 warning letters to companies selling hangover products. In March 2022, FDA denied two citizen petitions on the exclusion question but left the request for rulemaking open. In August 2022, it issued guidance announcing temporary enforcement discretion for certain NAC products labeled as dietary supplements. That discretion applies until FDA either completes rulemaking or denies the petition request.
FDA's Legal Framework
FDA reads the statute as allowing an exception only when two conditions are met: (1) regulating the substance as a dietary supplement would provide adequate safeguards, and (2) allowing that use would be unlikely to impede new drug development. FDA also concludes that the authority reaches only articles that qualify as dietary ingredients. The agency says the section 201(ff)(3)(B) exception must be paired with a section 301(ll)(2) determination. Otherwise, a product would become a lawful supplement and, because supplements are deemed to be food, it would also fall within the section 301(ll) prohibition. FDA also relies on its general rulemaking authority in section 701(a).
Application to NAC
Safety. FDA conducted a peer-reviewed systematic review of orally administered NAC. It identified 41 high-confidence studies with doses of up to 9,000 mg/day and durations of up to three years. The review found a "minimal" level of concern. The main adverse events were non-serious gastrointestinal effects, and only one study showed a statistically significant increase in nausea. Common supplement servings of 600, 1,000, and 1,200 mg/day overlap with the doses studied.
Drug development. NAC is still approved as a drug, including as Acetadote (NDA 021539) and under at least 19 ANDAs. FDA identified 832 clinical trials. Because NAC supplements have been sold for more than 30 years without apparent harm to drug development, FDA expects the rule to have little or no impact. FDA asks for comment on this point. FDA estimates the rule's costs as negligible (a present value of about $848) and treats it as a deregulatory action under Executive Order 14192.
Why the Proposal Is a Good Outcome
- It aligns the law with the market. NAC products labeled as dietary supplements have been sold in the United States since at least 1991. Since 2022, they have depended on temporary enforcement discretion. A final rule would replace that uncertain position with clear legal status.
- It strengthens consumer protection. Lawful NAC supplements would be deemed food and would be subject to every dietary supplement requirement, including CGMP, labeling, and adulteration and misbranding enforcement. Under enforcement discretion, FDA was relying on a policy of non-enforcement for products that were technically unlawful.
- It rests on evidence. FDA's peer-reviewed systematic review found a minimal level of concern at doses that cover typical supplement servings.
- It creates a reusable pathway. As the first use of section 201(ff)(3)(B), the rule sets out a two-part standard (adequate safeguards and no likely harm to drug development) and reserves space in 21 CFR 190.1 for other ingredients.
- Its cost is negligible, and FDA treats it as a deregulatory action.
One Ingredient, Two Lawful Roles: Health Maintenance and Disease Treatment
A product's regulatory category under the FD&C Act depends on its intended use, form, dose, and claims, not on its chemistry alone. As a drug, acetylcysteine treats disease. Acetadote prevents or lessens liver injury after acetaminophen overdose, and acetylcysteine is also an adjuvant therapy for abnormal mucous secretions in conditions such as chronic bronchopulmonary disease. As a dietary supplement, NAC is a dietary substance that supplements the diet. It is taken by mouth and may carry structure/function or general well-being claims under section 403(r)(6), not claims to diagnose, treat, cure, mitigate, or prevent disease.
The two roles are judged under different standards. FDA notes that drug review weighs risk against benefit, while a dietary supplement safety assessment generally considers risk alone. A drug may justify greater risk because it treats serious illness. A supplement must be safe on its own at ordinary dietary doses, and FDA found that NAC meets that test. The same pattern already applies to vitamin D, folic acid, omega-3 fatty acids, and niacin, which are each sold as supplements and exist as prescription drug products.
Coexistence also has not undermined drug development. NAC has been continuously approved as a drug since 1963. At least 19 ANDAs exist, most approved after supplement sales began, and FDA identified 832 clinical trials on NAC as a drug. FDA concluded that more than 30 years of supplement sales do not appear to have harmed NAC drug development, and no commenter on the 2022 guidance provided data suggesting otherwise. The two markets serve different needs: consumers who want general wellness support and patients who need treatment for overdose or serious respiratory disease.
The line to watch. Coexistence depends on supplement marketers staying on the supplement side of the line. FDA's 2020 warning letters targeted NAC products that claimed to prevent or treat hangovers. The rule would resolve NAC's ingredient status, but it would not permit therapeutic claims.
Implications and Recommended Actions
- Manufacturers and distributors: Confirm that NAC products meet every element of section 201(ff) and comply with CGMP (21 CFR part 111), labeling, and structure/function claim requirements. Avoid disease claims, such as hangover or overdose claims, that could make a product an unapproved drug.
- New entrants: The rule would give legal clarity that may support new product launches and retail acceptance. It may also bring closer regulatory and competitor scrutiny.
- Drug sponsors and developers: Consider whether to submit data on any impact on NAC drug development. This would also be an opportunity to comment on the two-part standard FDA will likely apply to future petitions for other excluded ingredients.
- Petition strategy: Reserved paragraph 190.1(b) signals that FDA may add other ingredients. Companies with ingredients affected by the drug exclusion should assess whether to petition FDA.
- Comments: Consider commenting on the immediate effective date, the safety assessment, evidence of pre-1963 marketing, and the legal framework.
How We Can Help
Venable's FDA regulatory team advises dietary supplement and pharmaceutical companies on ingredient status, compliance, and rulemaking participation. Please contact any of the authors listed above with questions or for help preparing comments.